Alnylam Pharmaceuticals Inc. (ALNY)

71.50
1.47 2.10
NASDAQ : Health Technology
Prev Close 70.03
Open 70.31
Day Low/High 69.84 / 72.25
52 Wk Low/High 60.27 / 124.22
Volume 720.79K
Avg Volume 957.10K
Exchange NASDAQ
Shares Outstanding 106.54M
Market Cap 7.46B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alnylam To Report New Clinical Results For ONPATTRO® (patisiran) At Peripheral Nerve Society (PNS) Annual Meeting And The 5th Congress Of The European Academy Of Neurology (EAN)

Alnylam To Report New Clinical Results For ONPATTRO® (patisiran) At Peripheral Nerve Society (PNS) Annual Meeting And The 5th Congress Of The European Academy Of Neurology (EAN)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present new results from the Global Open-Label Extension (OLE) study of ONPATTRO ® (patisiran) in patients with hereditary ATTR...

Alnylam Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.

Alnylam Doses First Patient In Phase 1 Study Of ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension

Alnylam Doses First Patient In Phase 1 Study Of ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Company's Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen (AGT) for...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 10:30...

Alnylam Announces New Leadership Appointments

Alnylam Announces New Leadership Appointments

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of Kelley Boucher as the Company's Senior Vice President (SVP), Chief Human Resources Officer (CHRO) and the promotion of Kevin...

Noteworthy Friday Option Activity: ALNY, CYRX, AKCA

Noteworthy Friday Option Activity: ALNY, CYRX, AKCA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alnylam Pharmaceuticals Inc , where a total volume of 6,797 contracts has been traded thus far today, a contract volume which is representative of approximately 679,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 46.2% of ALNY's average daily trading volume over the past month, of 1.5 million shares.

Alnylam To Webcast Presentation At Bank Of America Merrill Lynch Health Care Conference 2019

Alnylam To Webcast Presentation At Bank Of America Merrill Lynch Health Care Conference 2019

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT...

Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2019 and reviewed recent business highlights.

Alnylam To Webcast Conference Call Discussing First Quarter 2019 Financial Results

Alnylam To Webcast Conference Call Discussing First Quarter 2019 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2019 on Wednesday, May 1, 2019, before the U.

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran For The Treatment Of Primary Hyperoxaluria Type 1 And Presents New Positive Results From Phase 2 Open-Label Extension Study

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran For The Treatment Of Primary Hyperoxaluria Type 1 And Presents New Positive Results From Phase 2 Open-Label Extension Study

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi...

Alnylam Presents Positive Complete Results From ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyria

Alnylam Presents Positive Complete Results From ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive complete results from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1...

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc.

Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration

Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam and Sanofi have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases.

Lack of Euphoria: Cramer's 'Mad Money' Recap (Tuesday 4/2/19)

Lack of Euphoria: Cramer's 'Mad Money' Recap (Tuesday 4/2/19)

The decided lack of enthusiasm for Lyft is really good for this market, says Jim Cramer. It shows investors are behaving rationally.

Mastercard, Carrizo Oil & Gas, Duluth Holdings: 'Mad Money' Lightning Round

Mastercard, Carrizo Oil & Gas, Duluth Holdings: 'Mad Money' Lightning Round

Jim Cramer weighs in on Mastercard, Carrizo Oil & Gas, Duluth Holdings, Alnylam Pharmaceuticals, United States Steel.

Alnylam To Present Givosiran Phase 3 Data At The European Association For The Study Of The Liver (EASL) International Liver Congress™

Alnylam To Present Givosiran Phase 3 Data At The European Association For The Study Of The Liver (EASL) International Liver Congress™

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the European Association for the Study of the Liver (EASL) 54 th Annual International Liver...

Alnylam Submits CTA Application For ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension In High Unmet Need Settings

Alnylam Submits CTA Application For ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension In High Unmet Need Settings

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare products Regulatory Agency (MHRA) in the...

Alnylam To Webcast Presentation At Cowen & Company 39th Annual Health Care Conference

Alnylam To Webcast Presentation At Cowen & Company 39th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Cowen & Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 am ET at...

Alnylam Reports Positive Topline Results From ENVISION Phase 3 Study Of Givosiran In Acute Hepatic Porphyria

Alnylam Reports Positive Topline Results From ENVISION Phase 3 Study Of Givosiran In Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the...

Alnylam Announces Recipients Of First Annual Advocacy For Impact Grants Program

Alnylam Announces Recipients Of First Annual Advocacy For Impact Grants Program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced support for seven patient advocacy groups through the Advocacy for Impact Grants program.

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2018 and reviewed recent commercial and R&D highlights.

Alnylam Announces Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine

Alnylam Announces Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from the Phase 1 study of givosiran, an investigational, subcutaneous RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for...

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 21 st Annual BIO CEO & Investor Conference on Monday, February 11, 2019 at...

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2018 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2018 on Thursday, February 7, 2019, after the U.

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.

Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock.